MorphoSys's new antibody tech addresses HuCAL shortcomings
This article was originally published in Scrip
Executive Summary
MorphoSys unveiled its next-generation antibody technology today, promising it would be commercially available next year. The new technology, called Ylanthia, is still in beta-testing and the company would not say on what basis it would be made available to new and existing clients.